Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
Article
PubMed
Google Scholar
Clark PE. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009;9:821–30.
Article
CAS
PubMed
Google Scholar
Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci. 2014;111:3110–15.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, et al. Bladder cancer. Lancet. 2016;388:2796–810.
Article
PubMed
Google Scholar
Network TCGAR. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22.
Article
CAS
Google Scholar
Gopalakrishnan D, Koshkin S, Ornstein MC, Papatsoris A, Grivas P. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag. 2018;14:1019–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930–40.
Article
PubMed
PubMed Central
Google Scholar
Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res. 2016;4:563–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ren R, Tyryshkin K, Graham CH, Koti M, Siemens DR, Ren R, et al. Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance. Oncotarget. Impact J. 2017;8:70982–1001.
Google Scholar
Chen S, Zhang N, Shao J, Wang T, Wang X. Multi-omics perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration in urothelial cancer. J Cancer. 2019;10:697–707.
Article
PubMed
PubMed Central
Google Scholar
He Z, Kosinska W, Zhao ZL, Wu XR, Guttenplan JB. Tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis. Mutat Res–Genet Toxicol Environ Mutagen. 2012;742:92–5 (Elsevier B.V).
Article
CAS
Google Scholar
Nagao M, Suzuki E, Yasuo K, Yahagi T, Seino Y. Mutagenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine, a bladder carcinogen, and related compounds. Cancer Res. 1977;37:399–407.
CAS
PubMed
Google Scholar
Fantini D, Glaser AP, Rimar KJ, Wang Y, Schipma M, Varghese N, et al. A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene. 2018;37:1911–25.
Article
CAS
PubMed
PubMed Central
Google Scholar
Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7:562–78.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen Y, Mccarthy D, Ritchie M, Robinson M, Smyth G. edgeR: differential expression analysis of digital gene expression data User’s Guide. 2008.
Goff AL, Trapnell C, Kelley D, Loyal Goff MA. Package “cummeRbund” Analysis, exploration, manipulation, and visualization of Cufflinks high-throughput sequencing data. 2015.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen Z, Quan L, Huang A, Zhao Q, Yuan Y, Yuan X, et al. seq-ImmuCC: cell-centric view of tissue transcriptome measuring cellular compositions of immune microenvironment from mouse RNA-seq data. Front Immunol. 2018;9:1–11.
Article
CAS
Google Scholar
Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010;11:R25.
Article
PubMed
PubMed Central
CAS
Google Scholar
Yao R, Lemon WJ, Wang Y, Grubbs CJ, Lubet RA, You M. Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine. Neoplasia. 2004;6:569–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schilling JD, Mulvey MA, Vincent CD, Lorenz RG, Hultgren SJ. Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism. J Immunol. 2001;166:1148–55.
Article
CAS
PubMed
Google Scholar
Mysorekar IU, Isaacson-Schmid M, Walker JN, Mills JC, Hultgren SJ. Bone morphogenetic protein 4 signaling regulates epithelial renewal in the urinary tract in response to uropathogenic infection. Cell Host Microbe Cell Press. 2009;5:463–75.
Article
CAS
Google Scholar
Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12:1–13.
Article
CAS
Google Scholar
Janzowski C, Jacob D, Henn I, Zankl H, Poole-Zobel BL, Eisenbrand G. Investigations on organ-specific metabolism and genotoxic effects of the urinary bladder carcinogen N-nitrosobutyl-3-carboxypropylamine (BCPN) and its analogs N-nitrosodibutylamine (NDBA) and N-nitrosobutyl-4-hydroxybutylamine (4-OH-NDBA). Toxicology. 1989;59:195–209.
Article
CAS
PubMed
Google Scholar
D’Alessio FR, Craig JM, Singer BD, Files DC, Mock JR, Garibaldi BT, et al. Enhanced resolution of experimental ARDS through IL-4-mediated lung macrophage reprogramming. Am J Physiol Cell Mol Physiol. 2016;310:L733–46.
Article
Google Scholar
Okoye IS, Wilson MS. CD4 + T helper 2 cells–microbial triggers, differentiation requirements and effector functions. Immunology. 2011;134:368–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ray D, Nelson TA, Fu CL, Patel S, Gong DN, Odegaard JI, et al. Transcriptional profiling of the bladder in urogenital schistosomiasis reveals pathways of inflammatory fibrosis and urothelial compromise. PLoS Negl Trop Dis. 2012;6:e1912.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stremmel C, Greenfield EA, Howard E, Freeman GJ, Kuchroo VK. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J Exp Med. 1999;189:919–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest. 1993;91:88–93.
Article
CAS
PubMed
PubMed Central
Google Scholar
Koller FL, Hwang DG, Dozier EA, Fingleton B. Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis. 2010;31:1010–17.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gieseck RL, Ramalingam TR, Hart KM, Vannella KM, Cantu DA, Lu W-Y, et al. Interleukin-13 activates distinct cellular pathways leading to ductular reaction, steatosis, and fibrosis. Immunity. 2016;45:145–58.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gieseck RL, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2017;18(1):62–76.
Article
PubMed
CAS
Google Scholar
Joshi BH, Leland P, Lababidi S, Varrichio F, Puri RK. Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease. Cancer Med. 2014;3:1615–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kumari N, Agrawal U, Mishra AK, Kumar A, Vasudeva P, Mohanty NK, et al. Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer. Tumor Biol. 2017;39:1010428317697552.
Google Scholar
Foth M, Ismail NF, Kung JS, Tomlinson D, Knowles MA, Eriksson P, et al. FGFR3 mutation increases bladder tumorigenesis by suppressing acute inflammation. J Pathol. 2018;246:331–43.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jaiswal PK, Singh V, Srivastava P, Mittal RD. Association of IL-12, IL-18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population. Gene. 2013;519:128–34.
Article
CAS
PubMed
Google Scholar
Kaplanski G. Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev. 2018;281:138–53.
Article
CAS
PubMed
Google Scholar
Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J Leukoc Biol. 2014;97:665–75.
Article
PubMed
CAS
Google Scholar
Luo Y, Knudson MJ. Mycobacterium bovis bacillus Calmette-Guerin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol. 2010. https://doi.org/10.1155/2010/357591.
Article
PubMed
PubMed Central
Google Scholar
Szpakowski P, Biet F, Locht C, Paszkiewicz M, Rudnicka W, Druszczyńska M, et al. Dendritic cell activity driven by recombinant Mycobacterium bovis BCG producing human IL-18, in healthy BCG vaccinated adults. J Immunol Res. 2015;2015:1–13.
Article
CAS
Google Scholar
Van Batavia J, Yamany T, Molotkov A, Dan H, Mansukhani M, Batourina E, et al. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol. 2014;16(10):982–91.
Article
CAS
PubMed
Google Scholar
Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 2016;12:105–17.
Article
PubMed
PubMed Central
Google Scholar
Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res. 2014;4:461–73.
PubMed
PubMed Central
Google Scholar
Saito R, Smith CC, Utsumi T, Bixby LM, Kardos J, Wobker SE, et al. Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Res. 2018;78:3954–68.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bellucci R, Martin A, Bommarito D, Wang K, Hansen SH, Freeman GJ, et al. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015;4:e1008824.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mo X, Zhang H, Preston S, Martin K, Zhou B, Vadalia N, et al. Interferon-γ signaling in melanocytes and melanoma cells regulates expression of CTLA-4. Cancer Res. 2018;78:436–50.
Article
CAS
PubMed
Google Scholar
Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28:401–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Giannopoulos A, Constantinides C, Fokaeas E, Stravodimos C, Giannopoulou M, Kyroudi A, et al. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. Clin Cancer Res. 2003;9:5550–8.
CAS
PubMed
Google Scholar
Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–20.
Article
CAS
PubMed
PubMed Central
Google Scholar